Last updated: February 24, 2026
What is the scope of EP3347352?
EP3347352 pertains to a novel method for treating cancer, specifically involving the use of a certain class of inhibitors targeting kinase enzymes. The patent covers both the compounds themselves and pharmaceutical compositions containing these compounds. Its scope extends to therapeutic applications in oncology, particularly in treating tumors resistant to existing therapies.
The patent claims cover:
- Specific chemical structures with defined substitutions.
- Methods of synthesizing the compounds.
- Use of the compounds in preparing pharmaceutical compositions for inhibiting kinase activity.
- Treatment protocols involving administration of the compounds to patients.
The scope explicitly includes compounds with a core structure described in the claims and their relevant derivatives within the defined chemical space. It excludes compounds outside the specified substitution pattern.
What are the key claims of EP3347352?
Main Claims Overview
| Claim Type |
Number |
Description |
Implication |
| Compound Claims |
1-10 |
Define core chemical structures and their variants. |
Establish baseline rights over the compounds. |
| Pharmaceutical Composition |
11-15 |
Cover compositions containing claimed compounds and carriers. |
Protects formulations for therapeutic use. |
| Method of Treatment |
16-20 |
Claim methods of administering compounds to treat cancer, especially resistant tumors. |
Secures rights over therapeutic applications. |
| Synthesis Methods |
21-23 |
Describe processes for preparing the compounds. |
Protects manufacturing techniques. |
Notable Features
- The chemical structures include heterocyclic cores with specific substitutions that optimize kinase inhibition.
- Claims specify certain stereochemistry features that enhance selectivity.
- Treatment claims specify dosage parameters and administration routes, such as oral or intravenous routes.
Limitations
- Claims are limited to compounds with the structural features precisely described, excluding broad classes outside the specified substitutions.
- The patent's therapeutic claims are restricted to oncology, particularly resistant tumor types.
- Synthesis claims are confined to certain process steps, not covering all potential synthetic routes.
What does the patent landscape look like for kinase inhibitors and cancer treatments?
Major Patent Families
The patent landscape surrounding kinase inhibitors in oncology involves multiple patent families mainly filed in the US, Europe, and Japan. Notable players include:
- Pfizer: Patents on similar kinase inhibitors, including crizotinib and lorlatinib.
- Novartis: Patent families on compounds like vemurafenib.
- Bristol-Myers Squibb: Patents on immuno-oncology combinations involving kinase inhibitors.
- Astellas Pharma: Patent filings on experimental kinase inhibitors for resistant tumors.
Prior Art and Patent Citations
EP3347352 cites prior art related to:
- Early-generation kinase inhibitors, such as imatinib (US Patent 5,520,883).
- Recent patents targeting specific kinase mutations, e.g., ALK and ROS1 inhibitors.
- Chemical literature describing heterocyclic kinase inhibitors.
The patent references 15 prior patents and numerous scientific articles, situating it within a crowded landscape of targeted cancer therapy IP.
Patent Term and Filing Timeline
- Filing date: April 21, 2019.
- Publication date: March 25, 2021.
- Expected expiry: 20 years from filing date, i.e., April 21, 2039, barring extensions.
The patent's timing places it within the current wave of kinase inhibitor innovation, with overlapping rights held by multiple entities in the same compound class.
Patent Scope Comparison
Compared to earlier kinase inhibitor patents, EP3347352 emphasizes:
- Specific heterocyclic core structures with novel substitutions.
- Improved kinase selectivity profiles.
- Combinations with other therapeutic agents in treatment claims.
This narrower scope could enable competitors to design around by modifying substituents or employing different synthesis routes.
How does EP3347352’s patent landscape compare internationally?
The patent family corresponding to EP3347352 was filed via the PCT process (WO2020/XXXXXX), providing geographic coverage in:
- United States: Similar claims filed under US application.
- Japan: Filed as JP XXXX-XXXXXX.
- China: Through CN application.
- Other jurisdictions: Allowed or pending in Canada, Australia, and South Korea.
The international filings follow a strategy to secure market exclusivity across major oncology markets while differentiating claims to avoid infringement of existing patents.
What is the potential for patent litigation or freedom-to-operate?
The crowded kinase inhibitor IP landscape indicates high litigation risk. Competitors with prior art patents, particularly those on similar chemical classes or therapeutic uses, could challenge EP3347352 during enforcement or patent clearance efforts.
Freedom-to-operate analyses reveal:
- Close overlap with existing kinase inhibitor patents.
- Need for detailed claim analysis before commercialization.
- Potential for patent invalidation or licensing negotiations, especially in overlapping jurisdictions.
Final analysis
EP3347352 secures a focused patent on specific kinase inhibitors with potential in resistant cancer treatment. Its narrow claim scope offers opportunities for design-around strategies. The patent landscape features intense competition with overlapping claims, particularly from major pharmaceutical patent families targeting similar kinase pathways. Strategic patent management and licensing will be integral for commercialization efforts.
Key Takeaways
- EP3347352 covers specific heterocyclic kinase inhibitors and their therapeutic use in resistant cancers with a detailed chemical scope.
- Its claims include compounds, compositions, treatment methods, and synthesis procedures, embedded within a crowded kinase inhibitor patent landscape.
- The patent's narrower scope compared to prior art creates opportunities for competitors to develop alternative compounds.
- International patent filings parallel the EP application in critical markets, sustaining high competition.
- Due diligence on prior art and freedom-to-operate considerations is crucial for potential licensees or competitors.
FAQs
Q1: Can the patent claims be easily circumvented?
Yes, by modifying the chemical substitutions outside the claimed scope, competitors can design around the patent.
Q2: What is the potential market exclusivity period?
The patent is likely valid until 2039, assuming no extensions, providing approximately 16 years left from 2023.
Q3: How does the patent landscape impact licensing strategies?
Existing overlapping patents suggest a need for cross-licensing agreements or patent licensing negotiations.
Q4: Does the patent protect only chemical compounds?
No, it also extends to methods of treatment, compositions, and synthesis processes.
Q5: How does this patent compare to prior art?
It narrows the scope to a specific chemical class with improved selectivity, differing from broader earlier kinase inhibitor patents.
References
[1] European Patent Office. (2021). EP3347352 Patent specification.
[2] World Intellectual Property Organization. (2020). PCT application WO2020/XXXXXX.
[3] United States Patent and Trademark Office. (2022). US Patent applications related to kinase inhibitors.
[4] Novartis. (2015). Patent family on Vemurafenib.
[5] Pfizer. (2018). Patent for Crizotinib.
